Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine

Current Opinion in Cardiology

Volumn 12, Issue 4, 1997, Pages 375-381

  Ventura, Hector O ^a   Malik, Furrukh S ^a   Mehra, Mandeep R ^a   Stapleton, Dwight D ^a   Smart, Frank W ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; FUROSEMIDE; LISINOPRIL; NITRIC OXIDE; PROSTAGLANDIN;

ADRENERGIC SYSTEM; CALCIUM CELL LEVEL; CLINICAL TRIAL; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; HYPERTENSION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR DISEASE; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

EID: 0030753168     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199707000-00005     Document Type: Review

References (43)

1. Hosenpud JD, Novick RJ, Bennet LE, Keck BM, Fiol B, Daily OP: The Registry of the International Society for Heart and Lung Transplantation: Thirteenth Official Report-1996. J Heart Lung Transplant 1996, 15:655-674.
2. Kohan DE: Endothelins in normal and diseased kidneys. Am J Kidney Dis 1997, 29:2-26.
3. B receptor mRNA.
4. Haug C, Duell T, Voisard R, Lenich A, Kolb HJ, Mickley V, Hombach V, Grunert A: Cyclosporine A stimulates endothelin release. J Cardiovasc Pharmacol 1995, 26:S239-S241.
5. Haas GJ, Wooding-Scott M, Binkley PF, Myerowitz PD, Kelley R, Cody RJ: Effects of successful cardiac transplantation on plasma endothelin. Am J Cardiol 1995, 71:237-240. Elevated urinary endothelin levels after cyclosporin are secondary to renal endothelin synthesis as investigated by endothelin-1 mRNA in renal vasculature.
6. Texter SC, Burnett JC Jr, Romero JC, Conzello VJ, Taler SJ, Weisner R, Parayko M, Gores G, Hay E: Urinary endothelin and renal vasoconstriction with cyclosporin or FK 506 after liver transplantation. Kidney Int 1995, 47:1426-1433.
7. Abassi ZA, Pieruzzi F, Nakhoul F, Keiser HR: Effects of cyclosporin A on synthesis, excretion and metabolism of endothelin in the rat. Hypertension 1996, 27:1140-1148.
8. Takeda Y, Miyamori I, Wu P, Yoneda T, Furukawa K, Takeda R: Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 1995, 26:932-936.
9. Barholomeusz B, Hardy KJ, Nelson AS, Phillips PA: Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension 1996, 72:1341-1345. This study provides evidence to support a role for endothelin in cyclosporin-induced hypertension and demonstrates the effectiveness of ET receptor antagonism as a novel therapy.
10. Bloom IT, Bentley FR, Spain DA, Garrison RN: An experimental study of altered nitric oxide metabolism as a mechanism of cyclosporin-induced renal vasoconstriction. Br J Surg 1995, 82:195-198. Cyclosporin-induced renal vasoconstriction is secondary to reduction of NO synthesis as exogenous NO substrate reverses the vasoconstriction in rat kidney vasculature.
11. Stephan D, Billing A, Krieger JP, Grima M, Fabre M, Hofner M, Imbs JL, Barthelmebs M: Endothelin-dependent relaxation in the isolated rat kidney: impairment by cyclosporine A. J Cardiovasc Pharmacol 1995, 26:859-868.
12. Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saruta T: Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 1995, 25:764-768. The study indicates that cyclosporine inhibits NO synthase induction at the mRNA level.
13. Sudhir K, MacGregor JS, DeMarco T, DeGroot CJ, Taylor RN, Chou TM, Yock PG, Chatterjee K: Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 1994, 90:3018-3023.
14. 2+. Circ Res 1994, 74:477-484.
15. Diederich D, Skopec J, Diederich A, Dai FX: Cyclosporine produces endothelial dysfunction by increased production of Superoxide. Hypertension 1994, 23(6 Pt 2):957-961.
16. Edwards BD, Halmers RJ, O'Driscoll JB, Smith RJ, Lawson RS, Testa HJ, Ballardie FW: Angiotensin II as a risk factor for cyclosporine nephrotoxicity in patients with psoriasis. Clin Nephrol 1994, 41:350-356.
17. Murray BM, Paller MS, Ferns TF: Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985, 28:767-774.
18. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, Luetscher JA, Whitney DJ, Krasny D, Coplon NS, Perlroth MG: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988, 33:590-600.
19. Starling RC, Cody RJ: Cardiac transplant hypertension. Am J Cardiol 1990, 65:106-111.
20. Carrier M, Tronc F, Pelletier LC, Latour JG: Role of thromboxane and angiotensin in cyclosporine-induced renal vasoconstriction in the dog. J Heart Lung Transplant 1993, 12:851-854.
21. Olivari MT, Antolick A, Ring WS: Arterial hypertension in heart transplant recipients treated with triple-drug immunosuppressive therapy. J Heart Transplant 1989, 8:34-39.
22. Lyson T, McMullan DM, Ermel LD, Morgan BJ, Victor RG: Mechanisms of cyclosporine-induced sympathetic activation and acute hypertension in rats. Hypertension 1994, 23:667-675.
23. Scherrer U, Vissing SF, Morgan BJ, et al.: Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990, 323:693-699.
24. Stein CM, He H, Pincus T, Wood AJJ: Cyclosporine impairs vasodilatation without increased sympathetic activity in humans. Hypertension 1995, 26:705-710. In this study, cyclosporine impaired venodulatation in response to two agonists that act via adenylate cyclase without altering α-agonist-induced vasoconstriction or sympathetic activity.
25. Lucini D, Milani RV, Ventura HO, Mehra MR, Messerli F, Murgo JP, Malliani A, Pagani M: Cyclosporine-induced hypertension: evidence for maintained baroreflex circulatory control [abstract]. J Am Coll Cardiol 1996, 27:219A.
26. Lo Rossu A, Passaquin AC, Andre P, Skutella M, Ruegg UT: Effect of cyclosporine A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity. Br J Pharmacol 1996, 118:885-892. This study suggests that the calcium-potentiating effects of cyclosporine are dissociative and independent of its immunosuppressive properties.
27. 2 release are inhibited by protein kinase C inhibitors and diltiazem.
28. Ventura HO, Milani RV, Mehra MR, Lucini D, Smart FW, Stapleton DD, Pagani M, Murgo JP: Evidence of ventricular/vascular uncoupling in solid organ transplant recipients with hypertension [abstract]. J Am Coll Cardiol 1997, 29:61A.
29. Ventura HO, Lavie CJ, Messerli FH, et al.: Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens 1994, 8:233-237.
30. Farge D, Julien J, Amrein C, Guillemain R, Vulser C, Mihaileanu S, Dreyfuss G, Carpentier A: Effect of systemic hypertension on renal function and left ventricular hypertrophy in heart transplant recipients. J Am Coll Cardiol 1990, 15:1095-1001.
31. Ventura HO, Mehra MR, Lavie CJ, Stapleton DD, Smart FW: Patterns of left ventricular hypertrophy and geometric remodeling in cyclosporine-induced hypertension. J Heart Lung Transplant 1997, in press.
32. Tischler MD, Lee RT, Plappert T, Mudge GH, Sutton MST, Parker JD: Serial assessment of left ventricular function and mass after orthotopic heart transplantation: a 4-year longitudinal study. J Am Coll Cardiol 1992, 19:60-65.
33. Nichols WW, O'Rourke MF, Avolio AP, Yaginuma T, Murgo JP, Pepine CJ, Conti CR: Effects of age on ventricular-vascular coupling. Am J Cardiol 1985, 55:1179-1184.
34. Kahan BD: Cyclosporine nephrotoxicity: pathogenesis, prophylaxis, therapy, and prognosis. Am J Kidney Dis 1986, 3:332-337.
35. Ventura HO, Milani RV, Smart FW, Stapleton DD, Toups TS, Price HL: Cyclosporine-induced hypertension: efficacy of omega-3 fatty acids in patients following cardiac transplantation. Circulation 1993, 88(suppl):II-281-II-285.
36. Perico N, Benigni A, Zoja C, Delaini F, Remuzzi G: Functional significance of exaggerated renal thromboxane A2: synthesis induced by Cyclosporine A. Am J Physiol 1986, 251:F581-F587.
37. Reeves PA, Shapiro AP, Thompson ME, Johnsen AM: Loss of nocturnal decline in blood pressure after cardiac transplantation. Circulation 1986, 73:401-408.
38. Angermann CE, Spes CM, Willems S, Dominiak P, Kemkes BM, Theisen K: Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil. Circulation 1991, 84:583-593.
39. Kirk AJB, Omar I, Bateman DN, Dark JH: Cyclosporine-associated hypertension in cardiopulmonary transplantation. Transplantation 1989, 48:428-430.
40. Elliot WJ, Murphy MB, Farp R: Long-term preservation of renal function in hypertensive heart transplant patients treated with enalapril and diuretic. J Heart Lung Transplant 1991, 10:373-379.
41. Andreassen AK, Hartmann A, Offstad J, Geiran O, Kvernebo K, Simonsen S: Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. J Am Coll Cardiol 1997, 29:1324-1331. Role of ω-3 fatty acids in the prophylaxis of cyclosporine-induced hypertension in a randomized, placebo-controlled study of heart transplant recipients.
42. Brozena SC, Johnson MR, Ventura HO, Hobbs R, Miller L, Olivan MT, Clemson B, Bourge R, Quigg R, Mills RM, Naftel D: Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. J Am Coll Cardiol 1996, 27:1707-1712. The only multicenter randomized study comparing efficacy of diltiazem versus lisinopril in therapy of cyclosporine-induced hypertension.
43. Mehra MR, Ventura HO, Smart FW, Stapleton DD: Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. J Heart Lung Transplant 1995, 14:S246-S249.